Dr. Mohammed Almubarak, MD | Morgantown ...

Dr. Mohammed Almubarak, MD

Claim this profile

West Virginia University Healthcare

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
59 drugs studied

Area of expertise

1

Lung Cancer

Mohammed Almubarak, MD has run 8 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II
2

Non-Small Cell Lung Cancer

Mohammed Almubarak, MD has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.

West Virginia University Healthcare

Image of trial facility.

Wheeling Hospital/Schiffler Cancer Center

Clinical Trials Mohammed Almubarak, MD is currently running

Image of trial facility.

APL-101

for Lung Cancer

This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.

Recruiting

1 award

Phase 2

11 criteria

Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

Recruiting

1 award

Phase 2 & 3

21 criteria

More about Mohammed Almubarak, MD

Clinical Trial Related

8 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 7 Active Clinical Trials

Treatments Mohammed Almubarak, MD has experience with

  • Pembrolizumab
  • Biospecimen Collection
  • Ipatasertib
  • Binimetinib
  • Paclitaxel
  • Palbociclib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Mohammed Almubarak, MD specialize in?

Is Mohammed Almubarak, MD currently recruiting for clinical trials?

Are there any treatments that Mohammed Almubarak, MD has studied deeply?

What is the best way to schedule an appointment with Mohammed Almubarak, MD?

What is the office address of Mohammed Almubarak, MD?

Is there any support for travel costs?